OrthoTrophix Homepage

Latest News

November 9, 2019
OrthoTrophix Presents Evidence for Disease Modification in Knee Osteoarthritis by TPX-100 at American College of Rheumatology Annual Meeting

June 12, 2019
OrthoTrophix Presents Clinical Data at European Congress of Rheumatology Demonstrating Significant Correlation between Knee Function Improvement and Cartilage Thickness Increase/Stabilization after TPX-100

June 10, 2019
Reduction in Pathological Bone Shape Change Correlates with Decreased Frequency of Knee Pain after TPX-100 Treatment


OrthoTrophix is an emerging biopharmaceutical company focused on the development and commercialization of revolutionary therapies for the treatment of diseases and conditions involving hard tissues such as bone and cartilage. The primary focus of OrthoTrophix is development of a first-in-class disease modifying osteoarthritis drug (DMOAD), which improves joint health through regeneration and/or repair of cartilage and bone in the joints. The company’s leading therapeutic compound, TPX-100, has demonstrated a sound safety profile as well as statistically significant and clinically meaningful improvements in function and other beneficial clinical parameters in the knee. Clinical benefits in the knee correlated significantly with structural stabilization of cartilage and bone comprising the knee joint. Prior to initiation of human studies in knee osteoarthritis, TPX-100 demonstrated striking ability to repair normal articular (hyaline) cartilage in large animal models.